natgillin/translations-raw huggingface dataset:
A Health Assessment Questionnaire (HAQ), which included disability, vitality, mental health, general health status, and arthritis-associated health status subdomains, was administered every 3 months during the trial. 
Vprašalnik za oceno zdravstvenega stanja HAQ (Health Assessment Questionaire), ki je vključeval invalidnost, vitalnost, duševno zdravje, splošno zdravstveno stanje in poddomene zdravstvenega stanja, povezane z artritisom, so med preskušanjem uporabili vsake 3 mesece.
Responses of Patients with Psoriasis in Studies 2, 3 And 4 
Odzivi bolnikov s psoriazo v študijah 2, 3 in 4
Quality of life in psoriatic arthritis patients was assessed at every timepoint using the disability index of the HAQ. 
Kakovost življenja bolnikov s psoriatričnim artritisom je bila ocenjena v vsaki časovni točki z uporabo indeksa invalidnosti po HAQ.
The Patient's Alert Card should contain the following key elements for patients treated with LIFMIOR: 
Opozorilna kartica za bolnika mora vsebovati naslednje ključne sestavine za bolnike, ki se zdravijo z zdravilom LIFMIOR:
Invasive fungal infections accounted for more than half of the fatalities amongst patients who developed opportunistic infections. 
Invazivne glivične okužbe so povzročile več kot pol smrtnih primerov pri bolnikih, pri katerih so se razvile oportunistične okužbe.
Whilst waiting for the solution in the pen to reach room temperature, read Step 2 (below), and choose an injection site. 
Medtem ko čakate, da bo raztopina v peresniku dosegla sobno temperaturo, preberite korak 2 (spodaj) in izberite mesto injiciranja.
The syringe and needle should NEVER be re-used. 
Brizge in igle ne smete NIKOLI ponovno uporabiti.
The central volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l. 
Osrednji volumen porazdelitve etanercepta je 7,6 l, volumen porazdelitve v stanju dinamičnega ravnovesja pa je 10,4 l.
In this study, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. 
V tej študiji je bila strukturna poškodba sklepov ocenjena radiografsko in izražena kot sprememba skupne Sharpove ocene (TSS - Total Sharp Score) in njenih komponent, ocene erozije sklepov in ocene zožitve sklepne špranje (JSN - Joint Space Narrowing).
LIFMIOR is a medicine that is made from two human proteins. 
Zdravilo LIFMIOR je pridobljeno iz dveh človeških beljakovin.
The effect of LIFMIOR on radiographic progression was maintained in patients who continued on treatment during the second year. 
Učinek zdravila LIFMIOR na radiografsko napredovanje bolezni se je ohranjal pri bolnikih, ki so nadaljevali zdravljenje še drugo leto.
Similar results were obtained in the 2 smaller ankylosing spondylitis trials. 
Podobni rezultati so bili dobljeni pri 2 manjših preskušanjih ankilozirajočega spondilitisa.
However, caution should be exercised when treating the elderly and particular attention paid with respect to occurrence of infections. 
Vendar je pri zdravljenju starostnikov potrebna previdnost, posebno pozornost pa je treba posvetiti pojavljanju okužb.
In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. 
V prvem delu študije je 51 od 69 (74 %) bolnikov pokazalo klinični odziv in se vključilo v drugi del študije.
Please consult your doctor before you or the child receive any vaccines. 
Posvetujte se z zdravnikom, preden vi ali otrok prejmete katerokoli cepivo.
The types of major birth defects were consistent with those most commonly reported in the general population and no particular pattern of abnormalities was identified. 
Vrste resnih prirojenih napak so bile skladne s tistimi, o katerih so najpogosteje poročali pri splošni populaciji, pri tem pa niso odkrili nobenega posebnega vzorca nepravilnosti.
Patients with complete ankylosis of the spine were not included in the study. 
Bolniki s popolno ankilozo hrbtenice niso bili vključeni v študijo.
LIFMIOR contains no antibacterial preservative, and therefore solutions prepared with water for injections should be administered as soon as possible and within 6 hours following reconstitution. 
Zdravilo LIFMIOR ne vsebuje antibakterijskih konzervansov, zato je treba raztopino, pripravljeno z vodo za injekcije, injicirati čimprej oziroma najkasneje v 6 urah po rekonstituciji.
Name and address of the manufacturers responsible for batch release Wyeth Pharmaceuticals 
Ime in naslov izdelovalcev, odgovornih za sproščanje serij Wyeth Pharmaceuticals
Alternatively, 50 mg administered once weekly has been shown to be safe and effective (see section 5.1). 
Druga možnost je dajanje 50 mg enkrat na teden; dokazali so, da je ta možnost varna in učinkovita (glejte poglavje 5.1).
Placebo N=106 to 109* 
Placebo n = 106 do 109*
See section 4.4. 
Glejte poglavje 4.4.
To avoid damaging the needle inside the pen, do not bend the white needle cap while you are removing it, and do not re-attach it once it has been removed. 
Da ne bi poškodovali igle v peresniku, ne upogibajte belega pokrovčka igle, medtem ko ga odstranjujete, in ga ne natikajte več nazaj, potem ko je bil odstranjen.
• Your doctor will also give you a Patient Alert Card, which contains important safety information that you need to be aware of before and during treatment with LIFMIOR. 
Zdravnik vam bo izročil tudi opozorilno kartico za bolnika, ki vsebuje pomembne podatke o varnosti, s katerimi morate biti seznanjeni pred zdravljenjem z zdravilom LIFMIOR in med zdravljenjem z njim.
Hampshire, PO9 2NG United Kingdom 
Hampshire, PO9 2NG Velika Britanija
a. One MYCLIC pre-filled pen and one alcohol swab (take these from the carton of pens you keep in your refrigerator). 
a. En napolnjen peresnik MYCLIC in eno alkoholno blazinico (vzemite ju iz škatle s peresniki, ki jo hranite v hladilniku).
Before starting treatment with LIFMIOR, all patients must be evaluated for both active and inactive (‘latent') tuberculosis. 
Pred začetkom zdravljenja z zdravilom LIFMIOR je treba vse bolnike pregledati tako glede aktivne kot tudi glede neaktivne ('latentne') tuberkuloze.
No formal clinical trials have been conducted in children aged 2 to 3 years. 
Uradnih kliničnih preskušanj pri otrocih, starih od 2 do 3 let, niso izvedli.
Administration of live vaccines to infants for 16 weeks after the mother's last dose of LIFMIOR is generally not recommended. 
Uporaba živih cepiv v prvih 16 tednih po tem, ko so matere dojenčkov prejele zadnji odmerek zdravila LIFMIOR, pri dojenčkih običajno ni priporočljiva.
Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during LIFMIOR therapy and for three weeks after discontinuation of therapy. 
Ženske v rodni dobi morajo razmisliti o uporabi ustrezne kontracepcije za preprečitev nosečnosti med zdravljenjem z zdravilom LIFMIOR in še tri tedne po prenehanju zdravljenja.
LIFMIOR treatment resulted in improvement in physical function during the double-blind period, and this benefit was maintained during the longer-term exposure of up to 2 years. 
Zdravljenje z zdravilom LIFMIOR je povzročilo izboljšanje telesne funkcije v dvojno slepem obdobju, ta koristni učinek pa se je ohranjal med dolgotrajnejšo izpostavljenostjo, ki je trajala do 2 leti.
Step 4: Disposing of the used MYCLIC pen 
Korak 4: Odstranjevanje uporabljenega peresnika MYCLIC
Study 3 evaluated 583 patients and had the same inclusion criteria as study 2. 
Študija 3 je ocenila 583 bolnikov in je imela enaka vključitvena merila kot študija 2.
Do NOT use any other syringe. 
NE uporabljajte drugih brizg.
An analysis of clinical trial data did not reveal any baseline disease characteristics that would assist clinicians in selecting the most appropriate dosing option (intermittent or continuous). 
Analiza podatkov iz kliničnih preskušanj ni pokazala nobenih značilnosti osnovne bolezni, ki bi zdravnikom pomagala pri izbiri najustreznejšega odmerjanja (v presledkih ali stalno).
Treatment with LIFMIOR 25 mg resulted in substantial improvement at 12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5). 
Z zdravljenjem s 25 mg zdravila LIFMIOR so dosegli bistveno izboljšanje pri 12 mesecih - približno 44 % bolnikov je doseglo normalen rezultat HAQ (manj kot 0,5).
Do NOT remove the white collar that remains on the syringe. 
NE odstranjujte belega omota, ki ostane na brizgi.
Some children and teenage patients who have received LIFMIOR or other medicines that work the same way as LIFMIOR have developed cancers, including unusual types, which sometimes resulted in death. 
Pri nekaterih otrocih in mladostnikih, ki so prejemali zdravilo LIFMIOR ali druga podobna zdravila z enakim načinom delovanja kot zdravilo LIFMIOR, se je razvil rak, vključno z neobičajnimi oblikami, ki se je včasih končal s smrtjo.
For all of the above indications, available data suggest that a clinical response is usually achieved within 12 weeks of treatment. 
Razpoložljivi podatki kažejo, da je klinični odziv pri vseh zgoraj navedenih indikacijah ponavadi dosežen v obdobju 12 tednov zdravljenja.
Study 4 evaluated 142 patients and had similar inclusion criteria to studies 2 and 3. 
Študija 4 je ocenila 142 bolnikov in je imela podobna vključitvena merila kot študiji 2 in 3.
Reports have included fatal and life-threatening infections and sepsis. 
Poročali so o smrtnih in življenjsko nevarnih okužbah in sepsi.
A risk for the development of malignancies in children and adolescents treated with TNF-antagonists cannot be excluded. 
Tveganja za razvoj malignosti pri otrocih in mladostnikih, zdravljenih z antagonisti TNF, ni mogoče izključiti.
Clearance and volume estimates in patients aged 65 to 87 years were similar to estimates in patients less than 65 years of age. 
Ocenjene vrednosti očistka in volumna pri bolnikih, starih od 65 do 87 let, so bile podobne tistim pri bolnikih, mlajših od 65 let.
• if the child has an infection of any kind. 
če ima otrok kakršnokoli okužbo.
In long-term (up to 34 months) open-label studies where LIFMIOR was given without interruption, clinical responses were sustained and safety was comparable to shorter-term studies. 
V dolgoročnih (do 34 mesecev) odprtih študijah, v katerih so dajali zdravilo LIFMIOR brez prekinitev, so bili klinični odzivi trajni, varnost pa je bila primerljiva s tisto v krajših študijah.
In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life. 
Poleg tega uporaba Fc območja imunoglobulina kot elementa združitve pri konstrukciji dimernega receptorja podaljša razpolovno dobo zdravila v serumu.
If you received LIFMIOR during pregnancy, your baby may have a higher risk of getting an infection. 
Če ste med nosečnostjo prejeli zdravilo LIFMIOR, lahko pri vašem dojenčku obstaja povečano tveganje za razvoj okužbe.
No studies on the effects on the ability to drive and use machines have been performed. 
Študij o vplivu na sposobnost vožnje in upravljanja strojev niso izvedli.
Be careful not to push down on the plunger. 
Pazite, da ne pritisnete na bat brizge.
Simulation of dosing suggests that while older children (10-17 years of age) will have serum levels close to those seen in adults, younger children will have appreciably lower levels. 
Simulacija odmerjanja kaže, da bodo imeli starejši otroci (10 do 17 let) podobne serumske koncentracije kot odrasli, mlajši otroci pa znatno nižje.
In postmarketing experience, approximately half of all of the case reports of opportunistic infections worldwide were invasive fungal infections. 
V obdobju trženja je bilo približno pol vseh primerov okužb, opisanih v poročilih o primerih oportunističnih okužb po vsem svetu, invazivnih glivičnih okužb.
Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply). 
Pri vseh bolnikih je treba opraviti ustrezne presejalne teste, tj. tuberkulinski kožni test in rentgensko slikanje prsnega koša (morda obstajajo nacionalna priporočila glede teh preiskav).
Information in this leaflet is organised under the following 7 sections: 
Informacije v tem navodilu so razvrščene v naslednjih 7 poglavij:
The use of LIFMIOR in combination with other systemic therapies or phototherapy for the treatment of psoriasis has not been studied. 
Uporaba zdravila LIFMIOR v kombinaciji z drugimi sistemskimi zdravljenji ali fototerapijo za zdravljenje psoriaze ni raziskana.
In order to improve the traceability of biological medicinal products, the trademark and the batch number of the administered product should be clearly recorded (or stated) in the patient file. 
Za izboljšanje sledljivosti bioloških zdravil morata biti v bolnikovi kartoteki jasno dokumentirana (ali navedena) lastniško ime in številka serije prejetega zdravila.
Among patients who completed a full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, respectively. 
Med bolniki, ki so dokončali polnih 24 mesecev zdravljenja v študiji, je bil odstotek nenapredovanja 78 %, 70 % in 61 %.
Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue LIFMIOR therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Ker se imunoglobulini, tako kot mnoga druga zdravila, lahko izločajo v mleko pri človeku, se je treba odločiti, ali bo med zdravljenjem z zdravilom LIFMIOR bolnica prenehala dojiti ali pa bo med dojenjem prekinila zdravljenje s tem zdravilom, pri čemer je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja za mater.
Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility and general reproductive performance are not available. 
Predklinični podatki o perinatalni in postnatalni toksičnosti etanercepta ter učinkih etanercepta na plodnost in splošno sposobnost za razmnoževanje niso na voljo.
Treatment with LIFMIOR should continue until remission is achieved, for up to 24 weeks. 
Zdravljenje z zdravilom LIFMIOR je treba nadaljevati, dokler ne dosežemo remisije, vendar največ 24 tednov.
• Once the seal has been broken, remove the short, wide end of the plastic container. 
Po prelomu plombe odstranite krajši, širši del plastične embalaže.
At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5. 
V izhodišču so imeli bolniki zmerno stopnjo invalidnosti, s povprečno oceno po HAQ od 1,4 do 1,5.
The absolute bioavailability is 76%. 
Absolutna biološka uporabnost etanercepta je 76 %.
The known side effects of LIFMIOR include the following in groups of decreasing frequency: 
Znani neželeni učinki zdravila LIFMIOR so v nadaljevanju navedeni v skupinah po padajoči pogostnosti:
LIFMIOR treatment may increase mortality in patients with established sepsis. 
Zdravljenje z zdravilom LIFMIOR lahko zveča smrtnost pri bolnikih z dokazano sepso.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKE UČINKOVINE IN IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. 
V deležih spontanega splava, mrtvorojenosti ali manjših malformacij niso opazili sprememb.
Responses observed during the open-label period were similar to those observed in the double-blind period. 
Odzivi, ki so jih opažali med obdobjem odprtega zdravljenja, so bili podobni tistim v dvojno slepem obdobju.
• Psoriatic arthritis in patients from the age of 12 years 
• psoriatičnega artritisa pri bolnikih, starejših od 12 let.
Two large clinical trials evaluating the use of LIFMIOR in the treatment of CHF were terminated early due to lack of efficacy. 
Dve veliki klinični preskušanji za ovrednotenje uporabe zdravila LIFMIOR pri zdravljenju KSP sta bili predčasno prekinjeni zaradi slabe učinkovitosti zdravila.
Make sure that the tip does not touch anything. 
Pazite, da se konica ničesar ne dotika.
If you prefer, you may alternatively use the stomach area, but make sure you choose a site at least 5 cm away from the belly button (navel). 
Če vam je ljubše, lahko uporabite tudi predel trebuha, vendar izberite mesto, ki je vsaj 5 cm oddaljeno od popka.
• Very rare (may affect up to 1 in 10,000 people): failure of the bone marrow to produce crucial blood cells. 
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): prenehanje tvorbe nujnih krvnih celic v kostnem mozgu.
The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept serum concentrations. 
Učinek višje starosti na farmakokinetiko zdravila so proučevali s populacijsko farmakokinetično analizo serumskih koncentracij etanercepta.
If inactive (‘latent') tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of LIFMIOR, and in accordance with local recommendations. 
Če se ugotovi neaktivna ('latentna') tuberkuloza, je treba pred uvedbo zdravila LIFMIOR in v skladu z nacionalnimi priporočili začeti zdravljenje latentne tuberkuloze s tuberkulostatiki.
This Fc component contains the hinge, CH2 and CH3 regions, but not the CH1 region of IgG1. 
Domena Fc humanega IgG1 vsebuje "gibljivo mesto" (hinge) in področji CH2 in CH3, ne pa tudi področja CH1 IgG1.
• Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in patients from the age of 2 years 
• poliartritisa (pozitivnega ali negativnega za revmatoidni faktor) in razširjenega oligoartritisa pri bolnikih, starejših od 2 let.
If you have used more LIFMIOR than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately. 
Če ste uporabili večji odmerek zdravila LIFMIOR, kot bi smeli (bodisi ste ga naenkrat injicirali preveč bodisi prepogosto), se nemudoma posvetujte z zdravnikom ali farmacevtom.
To help you remember, it may be helpful to write in a diary which day(s) of the week LIFMIOR should be used. 
Da si boste lažje zapomnili, vam bo morda pomagalo, če si v koledarju zabeležite dan (dneve) v tednu, ko morate uporabiti zdravilo LIFMIOR.
There have been reports of worsening of hepatitis C in patients receiving LIFMIOR. 
Poročali so o poslabšanju hepatitisa C pri bolnikih, ki so prejemali zdravilo LIFMIOR.
Physicians should use caution when considering combination therapy with sulfasalazine. 
Zdravniki morajo biti previdni, kadar razmišljajo o kombiniranem zdravljenju s sulfasalazinom.
Step 4: Disposing of supplies 
Korak 4: Odstranjevanje odpadkov
If needed, you may cover the injection site with a bandage. 
Če je treba, lahko mesto injiciranja prekrijete z obližem.
The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to 3.5 years) increases over time, as expected. 
Delež bolnikov, pri katerih so se pojavila protitelesa proti etanerceptu v dolgoročnejših preskušanjih (do 3,5 let), se po pričakovanjih sčasoma povečuje.
Discontinuation of treatment should be considered in patients who show no response after 4 months. 
O prekinitvi zdravljenja je treba razmisliti pri bolnikih, ki ne kažejo odziva po 4 mesecih zdravljenja.
Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of LIFMIOR (10 mg, 25 mg or 50 mg). 
Natančen odmerek za otroka bo določil zdravnik in predpisal ustrezno jakost zdravila LIFMIOR (10 mg, 25 mg ali 50 mg).
The solvent is a clear, colourless liquid. 
Vehikel je bistra, brezbarvna tekočina.
The pen's inspection window should now be completely purple, confirming that the dose has been injected correctly (see Diagram 8). 
Okence za pregledovanje sedaj postane povsem vijolično, kar potrjuje, da je bil odmerek injiciran pravilno (glejte sliko 8).
ACR Responsesa ACR 20 
Odzivi ACR ACR 20 ACR 50 ACR 70
The modified TSS at 12 months is presented in the table below. 
Modificirani TSS po 12 mesecih je prikazan v spodnji preglednici.
There may be a little bleeding at the injection site. 
Na mestu injiciranja se lahko pojavi manjša krvavitev.
Inspect the solution in the syringe. 
Preglejte raztopino v brizgi.
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), LIFMIOR can slow down the structural damage to those joints caused by the disease. 
Pri bolnikih z več simetrično prizadetimi bolečimi ali oteklimi sklepi (npr. dlanmi, zapestji ali stopali) lahko zdravilo LIFMIOR upočasni razvoj strukturnih okvar teh sklepov, ki jih povzroča bolezen.
After discontinuation of LIFMIOR, symptoms of arthritis generally returned within a month. 
Po prekinitvi zdravljenja z zdravilom LIFMIOR so se simptomi artritisa največkrat ponovno pojavili že v enem mesecu.
In addition, one study found more birth defects when the mother had received LIFMIOR in pregnancy, compared with mothers who had not received LIFMIOR or other similar medicines (TNF-antagonists), but there was no particular kind of birth defect reported. 
Poleg tega so v eni študiji ugotovili več prirojenih napak, kadar je mati med nosečnostjo prejemala zdravilo LIFMIOR, v primerjavi z materami, ki niso prejemale zdravila LIFMIOR ali drugih podobnih zdravil (antagonistov TNF), vendar niso poročali o nobeni določeni vrsti prirojene okvare.
For storage conditions of the reconstituted medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are present. 
Raztopine ne uporabljajte, če je drugačne barve, motna, ali če so prisotni delci, ki ne ustrezajo opisu zgoraj.
If not used immediately, storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 6 hours at temperatures of up to 25°C, unless reconstitution has taken place in controlled and validated aseptic conditions. 
Če zdravila ne uporabite takoj, je za čas shranjevanja, ki normalno ne sme presegati 6 ur pri temperaturi do 25 C, in razmere pred uporabo odgovoren uporabnik, razen če je bila rekonstitucija zdravila izvedena v kontroliranih in validiranih aseptičnih pogojih.
In the double-blind and open-label psoriatic arthritis trials, 1 patient reported a serious infection (pneumonia). 
V dvojno slepih in odprtih preskušanjih psoriatičnega artritisa je 1 bolnik poročal o 1 resni okužbi (pljučnici).
However, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving TNF-antagonist therapy. 
Pojavnost je bila sicer redka, obdobje spremljanja bolnikov, ki so prejemali placebo, pa krajše kot pri bolnikih, ki so prejemali antagonist TNF.
It is very important that you tell your doctor if the child has ever had tuberculosis, or has been in close contact with someone who has had tuberculosis. 
Zelo pomembno je, da poveste zdravniku, če je vaš otrok kdaj imel tuberkulozo ali bil v tesnem stiku s kom, ki je imel tuberkulozo.
• The needle has been placed in a plastic container to keep it sterile. 
Igla se nahaja v plastični embalaži, da ostane sterilna.
The needle will remain protected inside the pen until the pen is activated. 
Igla bo ostala zaščitena v peresniku, dokler ne boste peresnika aktivirali.
A total of 401 patients were enrolled, from which 203 were treated with LIFMIOR. 
Sodeloval je 401 bolnik in od tega so bili 203 zdravljeni z zdravilom LIFMIOR.
If the window is not completely purple, contact your nurse or pharmacist for assistance, since the pen may not have injected the LIFMIOR solution completely. 
Če okence ni povsem vijolično, za pomoč prosite medicinsko sestro ali farmacevta, saj peresnik raztopine zdravila LIFMIOR morda ni injiciral v celoti.
No rebound flare of disease and no psoriasis-related serious adverse events were observed. 
Opazili niso nobenega preobratnega ponovnega izbruha bolezni in nobenih s psoriazo povezanih resnih neželenih učinkov.